Skip to Content

Generic Evzio Availability

Evzio is a brand name of naloxone, approved by the FDA in the following formulation(s):

EVZIO (naloxone hydrochloride - solution;intramuscular, subcutaneous)

  • Manufacturer: KALEO INC
    Approval date: April 3, 2014
    Strength(s): 0.4MG/0.4ML (0.4MG/0.4ML) [RLD]
  • Manufacturer: KALEO INC
    Approval date: October 19, 2016
    Strength(s): 2MG/0.4ML (2MG/0.4ML) [RLD]

Has a generic version of Evzio been approved?

No. There is currently no therapeutically equivalent version of Evzio available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evzio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Devices, systems and methods for medicament delivery
    Patent 7,731,686
    Issued: June 8, 2010
    Inventor(s): Edwards; Eric Shawn & Edwards; Evan Thomas & Licata; Mark J. & Meyers; Paul F. & Weinzierl; David A.
    Assignee(s): Intelliject, Inc.
    An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
    Patent expiration dates:
    • June 10, 2026
      ✓ 
      Drug product
    • June 1, 2026
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 7,731,690
    Issued: June 8, 2010
    Inventor(s): Edwards; Eric Shawn & Edwards; Evan Thomas
    Assignee(s): Intelliject, Inc.
    An apparatus includes a housing, a medicament container, an actuator, and a biasing member. The actuator is configured to move the medicament container within the housing when the actuator is moved from a first configuration to a second configuration. The actuator includes a gas container and a puncturer. When the actuator is in the first configuration, a portion of the puncturer is disposed apart from the gas container. When the actuator is in the second configuration, the portion of the puncturer is disposed within the gas container. The gas container has a longitudinal axis offset from a longitudinal axis of the medicament container. The biasing member is configured to bias the actuator toward the second configuration.
    Patent expiration dates:
    • January 15, 2025
      ✓ 
      Drug product
  • Devices, systems, and methods for medicament delivery
    Patent 7,749,194
    Issued: July 6, 2010
    Inventor(s): Edwards; Evan T. & Edwards; Eric S. & Licata; Mark J.
    Assignee(s): Intelliject, Inc.
    Certain exemplary embodiments comprise can comprise an auto-injector, which can comprise: a vial configured to store and/or contain an injectable medicament, the vial defining a vial longitudinal axis, and a housing comprising the vial. In various embodiments, the injectable medicament can be a medicine, medication, drug, pharmaceutical, prescriptive, agent, antidote, anti-venom, hormone, stimulant, vasodilator, anesthetic, and/or nutritional supplement that is substantially ready for injection.
    Patent expiration dates:
    • October 30, 2028
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 7,918,823
    Issued: April 5, 2011
    Inventor(s): Edwards; Eric Shawn & Edwards; Evan Thomas & Licata; Mark J. & Meyers; Paul F.
    Assignee(s): Intelliject, Inc.
    Apparatuses for automatic medicament injection and methods for manufacturing automatic medicament injectors are described herein. In some embodiments, an apparatus includes a housing, a needle, an energy storage member, an actuator, a locking member, and a needle guard. The needle is configured to move between a first position and a second position. In its first position, the needle is contained within the housing. In its second position, at least a portion of the needle extends from the housing. The energy storage member has a first configuration and a second configuration and is configured to produce a force when moving between its first configuration and its second configuration to move the needle from its first position to its second position. The actuator is configured to move the energy storage member from its first configuration to its second configuration. The locking member is movably coupled to the distal end portion of the housing such that the locking member can be moved between a first position and a second position. In its first position, the locking member is configured to engage the actuator to prevent the actuator from moving the energy storage member to the second configuration. The needle guard is removably coupled to at least one of the distal end portion of the housing or a base movably coupled to the distal end portion of the housing.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 7,947,017
    Issued: May 24, 2011
    Inventor(s): Edwards; Evan Thomas & Edwards; Eric Shawn & Licata; Mark J.
    Assignee(s): Intelliject, Inc.
    An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
    Patent expiration dates:
    • March 12, 2028
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,016,788
    Issued: September 13, 2011
    Inventor(s): Edwards; Evan Thomas & Edwards; Eric Shawn & Licata; Mark J.
    Assignee(s): Intelliject, Inc.
    An apparatus includes a housing, a medicament container and an actuator. The actuator includes a release member and an energy storage member having a first position and a second position. In the first position, the energy storage member has a first potential energy. In the second position the energy storage member has a second potential energy. The energy storage member is configured to convert a portion of the first potential energy into kinetic energy when moved from the first position to the second position to move the medicament container within the housing. The energy storage member has a longitudinal axis offset from a longitudinal axis of the medicament container. The release member is configured to selectively deploy the energy storage member from its first position to its second position.
    Patent expiration dates:
    • March 21, 2025
      ✓ 
      Drug product
  • Medicament delivery device configured to produce an audible output
    Patent 8,021,344
    Issued: September 20, 2011
    Inventor(s): Edwards; Eric S. & Edwards; Evan T. & Licata; Mark J. & Meyers; Paul F. & Weinzierl; David A.
    Assignee(s): Intelliject, Inc.
    Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medicament delivery device and an electronic circuit system. The medicament delivery device includes a housing, a medicament container, and a medicament delivery member. The electronic circuit system is coupled to the housing and includes an audible output device and a cover. The housing of the medicament delivery device and the cover of the electronic circuit system collectively define an acoustic enclosure. The audible output device is configured to be disposed within the acoustic enclosure.
    Patent expiration dates:
    • November 2, 2029
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,206,360
    Issued: June 26, 2012
    Inventor(s): Edwards; Eric Shawn & Edwards; Evan Thomas & Licata; Mark J. & Meyers; Paul F. & Weinzierl; David A.
    Assignee(s): Intelliject, Inc.
    An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
    Patent expiration dates:
    • February 27, 2027
      ✓ 
      Drug product
  • Medical injector with compliance tracking and monitoring
    Patent 8,226,610
    Issued: July 24, 2012
    Inventor(s): Edwards; Eric S. & Edwards; Evan T. & Licata; Mark J. & Meyers; Paul F. & Weinzierl; David A. & Williamson, IV; T. Spencer
    Assignee(s): Intelliject, Inc.
    A system includes a medicament delivery device and a container configured to receive at least a portion of the medicament delivery device. The medicament delivery device includes an actuator and a first electronic circuit system. The actuator is configured to initiate delivery of a medicament into a body when the actuator is moved from a first position to a second position. The first electronic circuit system is configured to output a first electronic signal when the actuator is moved from the first position to the second position. The container includes a second electronic circuit system configured to receive the first electronic signal. The second electronic circuit system is configured to output a second electronic signal associated with the first electronic signal.
    Patent expiration dates:
    • April 10, 2029
      ✓ 
      Drug product
  • Medicament delivery device having an electronic circuit system
    Patent 8,231,573
    Issued: July 31, 2012
    Inventor(s): Edwards; Eric S. & Edwards; Evan T. & Licata; Mark J. & Meyers; Paul F. & Weinzierl; David A.
    Assignee(s): Intelliject, Inc.
    Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
    Patent expiration dates:
    • November 25, 2028
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,313,466
    Issued: November 20, 2012
    Inventor(s): Edwards; Evan T & Edwards; Eric S & Licata; Mark J
    Assignee(s): Intelliject, Inc.
    An apparatus includes a housing, a medicament container and an actuator. The actuator includes a release member and an energy storage member having a first position and a second position. In the first position, the energy storage member has a first potential energy. In the second position the energy storage member has a second potential energy. The energy storage member is configured to convert a portion of the first potential energy into kinetic energy when moved from the first position to the second position to move the medicament container within the housing. The energy storage member has a longitudinal axis offset from a longitudinal axis of the medicament container. The release member is configured to selectively deploy the energy storage member from its first position to its second position.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,361,029
    Issued: January 29, 2013
    Assignee(s): Intelliject, LLC
    An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Devices, systems, and methods for medicament delivery
    Patent 8,425,462
    Issued: April 23, 2013
    Assignee(s): Intelliject, Inc.
    An apparatus includes a housing, a medicament container, an actuator, and a biasing member. The actuator is configured to move the medicament container within the housing when the actuator is moved from a first configuration to a second configuration. The actuator includes a gas container and a puncturer. When the actuator is in the first configuration, a portion of the puncturer is disposed apart from the gas container. When the actuator is in the second configuration, the portion of the puncturer is disposed within the gas container. The gas container has a longitudinal axis offset from a longitudinal axis of the medicament container. The biasing member is configured to bias the actuator toward the second configuration.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,608,698
    Issued: December 17, 2013
    Assignee(s): Intelliject, Inc.
    An apparatus includes a housing, a needle, a first energy storage member and a second energy storage member. The needle is movably disposed within the housing and is configured to be to be placed in fluid communication with a medicament container. The needle is configured to move between a first position and a second position. In its first position, the needle is contained within the housing. In its second position, at least a portion of the needle extends from the housing. The first energy storage member is disposed within the housing, and is configured to produce a first force when actuated. The second energy storage member is disposed within the housing, and is configured to be actuated in response to the first force to produce a second force to move the needle from the first needle position to the second needle position.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    Patent 8,627,816
    Issued: January 14, 2014
    Assignee(s): Intelliject, Inc.
    Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
    Patent expiration dates:
    • February 4, 2032
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 8,926,594
    Issued: January 6, 2015
    Assignee(s): kaleo, Inc.
    An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
    Patent expiration dates:
    • March 31, 2026
      ✓ 
      Drug product
  • Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    Patent 8,939,943
    Issued: January 27, 2015
    Assignee(s): kaleo, Inc.
    Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH-adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
    Patent expiration dates:
    • February 28, 2031
      ✓ 
      Drug product
  • Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    Patent 9,022,022
    Issued: May 5, 2015
    Assignee(s): kaleo, Inc.
    Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
    Patent expiration dates:
    • February 28, 2031
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 9,056,170
    Issued: June 16, 2015
    Assignee(s): kaleo, Inc.
    An apparatus includes a housing, a needle, a first energy storage member and a second energy storage member. The needle is movably disposed within the housing and is configured to be to be placed in fluid communication with a medicament container. The needle is configured to move between a first position and a second position. In its first position, the needle is contained within the housing. In its second position, at least a portion of the needle extends from the housing. The first energy storage member is disposed within the housing, and is configured to produce a first force when actuated. The second energy storage member is disposed within the housing, and is configured to be actuated in response to the first force to produce a second force to move the needle from the first needle position to the second needle position.
    Patent expiration dates:
    • November 23, 2024
      ✓ 
      Drug product
  • Medicament delivery device having an electronic circuit system
    Patent 9,238,108
    Issued: January 19, 2016
    Assignee(s): kaleo, Inc.
    Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
    Patent expiration dates:
    • January 22, 2027
      ✓ 
      Drug product
  • Devices, systems and methods for medicament delivery
    Patent 9,278,182
    Issued: March 8, 2016
    Assignee(s): kaleo, Inc.
    An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
    Patent expiration dates:
    • February 1, 2026
      ✓ 
      Drug product
  • Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    Patent 9,474,869
    Issued: October 25, 2016
    Assignee(s): kaleo, Inc.
    Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
    Patent expiration dates:
    • February 28, 2031
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide